ICU Medical (NASDAQ:ICUI) COO Sells $1,633,381.97 in Stock

ICU Medical, Inc. (NASDAQ:ICUI) COO Christian Voigtlander sold 8,929 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $182.93, for a total value of $1,633,381.97. Following the completion of the sale, the chief operating officer owned 37,377 shares of the company’s stock, valued at $6,837,374.61. This trade represents a 19.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

ICU Medical Trading Up 2.1%

Shares of ICUI stock opened at $183.11 on Friday. ICU Medical, Inc. has a 1-year low of $111.42 and a 1-year high of $192.85. The company has a market cap of $4.58 billion, a price-to-earnings ratio of 155.18, a PEG ratio of 2.51 and a beta of 0.74. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. The stock has a 50 day simple moving average of $155.63 and a 200-day simple moving average of $141.67.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.46. The firm had revenue of $547.88 million for the quarter, compared to analysts’ expectations of $533.44 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The firm’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter last year, the company earned $2.10 EPS. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, equities research analysts expect that ICU Medical, Inc. will post 6.51 EPS for the current fiscal year.

Hedge Funds Weigh In On ICU Medical

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Allworth Financial LP acquired a new stake in ICU Medical in the 2nd quarter valued at about $26,000. Hilton Head Capital Partners LLC acquired a new position in shares of ICU Medical during the 4th quarter worth approximately $32,000. Covestor Ltd boosted its holdings in shares of ICU Medical by 22.1% during the 4th quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 126 shares during the last quarter. Strs Ohio grew its position in shares of ICU Medical by 60.0% in the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after purchasing an additional 300 shares in the last quarter. Finally, Rockefeller Capital Management L.P. grew its position in shares of ICU Medical by 21.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 146 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q2 results beat expectations. ICU Medical reported adjusted earnings of $2.37 per share, well above the $1.91 analyst consensus, while revenue of $547.88 million exceeded estimates of $533.44 million. Revenue increased modestly year over year, and the company maintained fiscal 2026 EPS guidance of $8.60 to $9.00. ICU Medical Q2 2026 Earnings Call Transcript
• Positive Sentiment: Analyst sentiment remains supportive. Following the earnings release, Needham raised its price target to $187, Piper Sandler to $195, and BTIG Research to $200, while maintaining positive ratings. Raymond James also reiterated its strong-buy rating with a $200 target. The consensus rating is “Moderate Buy,” with an average target of $192.80.
• Positive Sentiment: Investor attention remains focused on the earnings call. Analysts’ questions centered on the company’s quarterly performance and outlook, suggesting that the earnings beat and management’s commentary remain the key drivers of current trading interest. The 5 Most Interesting Analyst Questions From ICU Medical’s Q2 Earnings Call
• Neutral Sentiment: Valuation is demanding. ICU Medical trades near its 52-week high at a very elevated forward valuation, making the stock more sensitive to any slowdown in growth or signs that the recent earnings momentum cannot be sustained.
• Negative Sentiment: Several insiders sold shares. Vice President Daniel Woolson sold 5,417 shares for approximately $982,000, COO Christian Voigtlander sold 8,929 shares for about $1.63 million, CIO Ben Sousa sold 2,250 shares for $401,000, and Director Elisha Finney sold 378 shares for roughly $69,000. The transactions reduced their holdings by meaningful percentages and may raise concerns about insider conviction, although such sales can also reflect personal liquidity or diversification. ICU Medical Insider Sales

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Needham & Company LLC lifted their price objective on ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Piper Sandler boosted their price objective on ICU Medical from $163.00 to $195.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Sanford C. Bernstein downgraded ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Finally, Zacks Research lowered ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $192.80.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.